Literature DB >> 28756710

Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis.

Yosuke Hattori1, Daihei Kida1, Atsushi Kaneko1.   

Abstract

OBJECTIVE: This study aimed to evaluate whether the level of serum matrix metalloproteinase-3 (MMP-3), a marker of synovium inflammation, is affected by clinical characteristics of patients in rheumatoid arthritis (RA) patients.
METHODS: We analyzed data from 1087 female patients with RA. Pearson's correlation coefficients were calculated to explore associations between variables. Stepwise multiple linear regression analysis was performed to evaluate patient background variables that could potentially affect serum MMP-3 levels.
RESULTS: Serum MMP-3 was moderately correlated with C-reactive protein (CRP) (r: 0.478). Factors that independently influenced serum MMP-3 levels were CRP (β: 0.450), prednisolone (PSL) use (β: 0.100), estimated glomerular filtration rate (eGFR) (β: -0.085), swollen joint count assessed on 28 joints (β: 0.072), and body mass index (β: -0.061) in female patients with RA. In RA patients with PSL use, factors that independently influenced serum MMP-3 levels were CRP (β: 0.480), eGFR (β: -0.175), and PSL dose (β: 0.171).
CONCLUSIONS: Our findings suggest that steroid therapy and renal dysfunction affect serum MMP-3 levels in patients with RA.

Entities:  

Keywords:  Rheumatoid arthritis; matrix metalloproteinase-3; remission; steroid

Mesh:

Substances:

Year:  2017        PMID: 28756710     DOI: 10.1080/14397595.2017.1354431

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  5 in total

1.  Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Paul J Martin; Stephanie J Lee; Amin A Momin; Laura Tabellini; Lynn E Onstad; Joseph Pidala; Mary E D Flowers; Richard L Lawler; Hiroyuki Katayama; Samir Hanash; John A Hansen
Journal:  Blood Adv       Date:  2020-06-09

2.  Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

Authors:  Nao Tokai; Shuzo Yoshida; Takuya Kotani; Ayaka Yoshikawa; Yuko Kimura; Youhei Fujiki; Yoko Matsumura; Tohru Takeuchi; Shigeki Makino; Shigeki Arawaka
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

3.  Periodic injections of adipose-derived stem cell sheets attenuate osteoarthritis progression in an experimental rabbit model.

Authors:  Tomoharu Takagi; Tamon Kabata; Katsuhiro Hayashi; Xiang Fang; Yoshitomo Kajino; Daisuke Inoue; Takaaki Ohmori; Takuro Ueno; Junya Yoshitani; Ken Ueoka; Yuki Yamamuro; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-10-19       Impact factor: 2.362

4.  Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jun Ishizaki; Ayako Takemori; Kenta Horie; Daisuke Hiraoka; Koichiro Suemori; Takuya Matsumoto; Ken-Ei Sada; Koichi Amano; Masayoshi Harigai; Yoshihiro Arimura; Hirofumi Makino; Katsuto Takenaka; Nobuaki Takemori; Hitoshi Hasegawa
Journal:  Arthritis Res Ther       Date:  2021-03-20       Impact factor: 5.156

5.  Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis.

Authors:  Yoichi Kurosawa; Satoshi Ito; Shunsuke Sakai; Eriko Hasegawa; Daisuke Kobayashi; Asami Abe; Hiroshi Otani; Kiyoshi Nakazono; Akira Murasawa; Ichiei Narita; Hajime Ishikawa
Journal:  Intern Med       Date:  2022-07-15       Impact factor: 1.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.